2-ethyl-1,2,3,4-tetrahydro-β-carboline | 18144-33-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-ethyl-1,2,3,4-tetrahydro-β-carboline
• 英文别名: 2-ethyl-2,3,4,9-tetrahydro-1H-β-carboline；2-ethyl-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole；2-Athyl-1,2,3,4-tetrahydro-β-carbolin；2-Ethyl-1,2,3,4-tetrahydro-norharman；2-ethyl-1,3,4,9-tetrahydropyrido[3,4-b]indole
• CAS: 18144-33-7
• 化学式: C₁₃H₁₆N₂
• 分子量: 200.283
• InChiKey: SYAKEYMHRPNORC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  19
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-ethyl-1,2,3,4-tetrahydro-β-carboline 、 次氯酸叔丁酯 以43%的产率得到
  参考文献：
  名称：

  KORNET M. J.; THIO A. P., J. MED. CHEM. , 1976, 19, NO 7, 892-898

  摘要：

  DOI：
• 作为产物：
  描述：

  1,2,3,4-四氢-9H-吡啶[3,4-B]并吲哚 、 碘乙烷 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 2.0h， 生成 2-ethyl-1,2,3,4-tetrahydro-β-carboline
  参考文献：
  名称：

  高效液相色谱法测定尿中1,2,3,4-四氢-β-咔啉和1-甲基-1,2,3,4-四氢-β-咔啉

  摘要：

  摘要建立了一种高效液相色谱法，定量分析水中的1,2,3,4-四氢-β-咔啉（TBC）和1-甲基-1,2,3,4-四氢-β-咔啉（MTBC）。人尿。将添加了内标物的尿液样品与荧光胺进行反应，并进行溶剂萃取以除去前体色胺，后者很容易与样品和试剂中的醛缩合。这样的预处理完全抑制了分析过程中TBC和MTBC的人为形成。通过反相离子对色谱和荧光检测分离纯化的原始四氢-β-咔啉和内标。他们的同时分离在短时间内自动完成（

  DOI：

  10.1002/jps.2600830330

文献信息

• SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS
  申请人：Smil David

  公开号：US20070293530A1

  公开（公告）日：2007-12-20

  This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I), and racemic and scalemic mixtures, diastereomers and enantiomers thereof: or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt, prodrug or complex thereof, wherein Y, L, Z, W, M, R a , R b and R c are as defined in the specification.

  这项发明涉及用于抑制组蛋白去乙酰化酶的化合物。更具体地，该发明提供了符合式(I)的化合物，以及它们的外消旋和内消旋混合物、非对映体和对映体： 或其N-氧化物、水合物、溶剂合物、药学上可接受的盐、前药或其复合物，其中Y、L、Z、W、M、R a 、R b 和R c 如规范中所定义。
• Indole derivatives and anti-ulcer compositions thereof
  申请人：Nisshin Flour Milling Co., Ltd.

  公开号：US05252580A1

  公开（公告）日：1993-10-12

  Disclosed are indole derivatives of formula (I) ##STR1## wherein Y represents H, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy or halogen; Z represents --CH.sub.2 N(R.sub.5)--; R represents H or --CH.sub.2 CH.sub.2 X where X represents pyridyl, aralkyloxy or substituted amino of NR.sub.6 R.sub.7 where R.sub.6 represents H, C.sub.1 -C.sub.6 alkyl, aralkyl, C.sub.1 -C.sub.6 alkoxycarbonyl, aralkyloxycarbonyl or halogenated C.sub.1 -C.sub.6 alkoxycarbonyl and R.sub.7 represents H, C.sub.1 -C.sub.6 alkyl or aralkyl, or together with R.sub.2 may form a ring of --(CH.sub.2).sub.n -- (n is 1-4) or ##STR2## R.sub.1 represents H, C.sub.1 -C.sub.6 alkyl, aralkyl or arylsulfonyl; R.sub.2 represents C.sub.1 -C.sub.6 alkyl, hydroxy, C.sub.1 -C.sub.6 alkoxy or aralkyloxy; R.sub.3 represents H, C.sub.1 -C.sub.6 alkyl, aralkyl or halogenated C.sub.1 -C.sub.6 alkyl; R.sub.4 and R.sub.5 may be the same or different and each represents H, C.sub.1 -C.sub.6 alkyl or aralkyl or both may together form a ring of --(CH.sub.2).sub.m -- (m is 3 or 4); or pharmaceutically acceptable acid addition salts thereof. They are useful as an antiulcer agent.

  本发明涉及公式（I）的吲哚衍生物##STR1##其中Y代表H，C.sub.1 -C.sub.6烷基，C.sub.1 -C.sub.6烷氧基或卤素；Z代表--CH.sub.2 N(R.sub.5)--；R代表H或--CH.sub.2 CH.sub.2 X，其中X代表吡啶基，芳基氧基或NR.sub.6 R.sub.7的取代氨基，其中R.sub.6代表H，C.sub.1 -C.sub.6烷基，芳基烷基，C.sub.1 -C.sub.6烷氧羰基，芳基氧羰基或卤代C.sub.1 -C.sub.6烷氧羰基，R.sub.7代表H，C.sub.1 -C.sub.6烷基或芳基烷基，或与R.sub.2一起形成--(CH.sub.2).sub.n --（n为1-4）的环或##STR2##R.sub.1代表H，C.sub.1 -C.sub.6烷基，芳基烷基或芳基磺酰基；R.sub.2代表C.sub.1 -C.sub.6烷基，羟基，C.sub.1 -C.sub.6烷氧基或芳基氧基；R.sub.3代表H，C.sub.1 -C.sub.6烷基，芳基烷基或卤代C.sub.1 -C.sub.6烷基；R.sub.4和R.sub.5可以相同也可以不同，每个代表H，C.sub.1 -C.sub.6烷基或芳基烷基，或两者一起形成--(CH.sub.2).sub.m --（m为3或4）的环；或其药学上可接受的酸盐。它们可用作抗溃疡剂。
• Inhibitors of AKT Activity
  申请人：Chen Chixu

  公开号：US20090062327A1

  公开（公告）日：2009-03-05

  The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

  本发明提供了抑制Akt活性的化合物。特别地，所披露的化合物选择性地抑制一种或两种Akt亚型。本发明还提供了包含这种抑制剂化合物的组合物以及通过向需要癌症治疗的患者施用该化合物来抑制Akt活性的方法。
• 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use
  申请人：Caggiano J. Thomas

  公开号：US20070299105A1

  公开（公告）日：2007-12-27

  This invention provides compounds of formula I or a pharmaceutically acceptable salt thereof that are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.

  这项发明提供了I式化合物或其药学上可接受的盐，可用于治疗疾病的炎症成分，特别是在治疗动脉粥样硬化、心肌梗死、充血性心力衰竭、炎症性肠病、关节炎、2型糖尿病以及自身免疫疾病如多发性硬化和类风湿性关节炎方面特别有用。
• Quinolizidinone M1 Receptor Positive Allosteric Modulators
  申请人：Kuduk Scott D.

  公开号：US20110046145A1

  公开（公告）日：2011-02-24

  The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的化合物，其为M1受体正向变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面具有用途。本发明还涉及包含该化合物的制药组合物，以及在治疗由M1受体介导的疾病中使用该化合物和组合物。